BRAF and neoplasm: The expression of numerous miRNAs changes before and after treatment in tumour biopsies, highlighting the concept that measurement of miRNA deregulation could allow for the development of tools to predict BRAF-mutant patients’ response or resistance to BRAFi or BRAFi plus MEKi treatment [187].